Pharmacokinetic interaction of ciprofloxacin with diclofenac: A single-dose, two-period crossover study in healthy adult volunteers

Clinical Drug Investigation

Volumn 29, Issue 4, 2009, Pages 275-281

  Iqbal, Zafar ^a   Khan, Abbas ^a   Naz, Attiqa ^a   Khan, Jamshaid A ^a   Khan, Ghulam S ^b  

^a UNIVERSITY OF PESHAWAR   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CIPROX; DICLOFENAC; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CROSS-OVER STUDIES; DICLOFENAC; DRUG COMBINATIONS; DRUG INTERACTIONS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; TABLETS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 62949183640     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929040-00006     Document Type: Article

References (23)

1. Bambeke FV, Michor JM, Eldere JV, et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-80
2. Seral C, Barcia-Macay M, Mingeot-Leclereq MP, et al. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxcifloxacin and garenoxacin) against extracellular and intracellular infection by listeria monocytes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005; 55: 511-7
3. Higgins G, Fluit AC, Schmitz FJ. Fluoroquinolones: structure and target sites. Curr Drug Targets 2004; 4: 181-90
4. Ljungberg B, Nilson-Ehle I. Pharmacokinetics of ciprofloxacin in elderly: increased oral bioavailability and reduced renal clearence. Eur J Clin Microbiol Infect Dis 1989; 8: 515-20
5. Esposito S. Pharmacokinetics of ciprofloxacin in impaired liver function. Int J Clin Pharmacol Res 1989; 9: 37-41
6. Hoffken G, Lode H, Prinzing C, et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agent Chemother 1985; 27 (3): 375-9
7. Lomaestro BM, Bailie GR. Absorption interaction with fluoroquinolones: 1995 update. Drug Safety 1995; 12: 314-33
8. Wallis SC, Charles BG, Gahan LR, et al. Interaction of norfloxacin with divalent and trivalent pharmaceutical cations: in vitro complexation and in vivo pharmacokinetic studies in dogs. J Pharm Sci 1996; 85: 803-9
9. Turel I. The interaction of metal ions with quinolone antibacterial agents. Coordin Chem Rev 2002; 232: 27-47
10. Rahal A, Kumar A, Ahmad AH, et al. Pharmacokinetics of diclofenac sodium and its interaction with enrofloxacin in sheep. Res Vet Sci 2008; 84: 452-6
11. Gillum JG, Israel DS, Polak PE. Pharmacokinetic drug interaction with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82
12. Akhtar H, Muhammad F, Akhtar MS, et al. Effect of antipyrine on disposition kinetics of ciprofloxacin in dogs. Pharmacologyonline 2007; 1: 581-7
13. Price RA. Effects of cimetidine on ciprofloxacin pharmacokinetics. Pharmacother 1990; 10: 234-9
14. Marcelin-Jimenez G, Angeles AP, Martinez-Rossier L, et al. Ciprofloxacin bioavailability is enhanced by oral coadministration with phenazopyridine. Clin Drug Invest 2006; 26 (6): 323-8
15. Kumar N, Singh SD, Jayachandra C. Pharmacokinetics of enrofloxacin and its active metabolites ciprofloxacin and its interaction with diclofenac sodium after intravenous administration in buffalo calves. Vet J 2003; 165: 302-6
16. Knupp CA, Barbbaiva RH. A multiple-dose pharmacokinetic interaction study between didanosine (Videx®) and ciprofloxacin (Cipro®) in male subjects seropositive for HIV but asymptomatic. Biopharm Drug Dispos 1997; 18: 65-7
17. Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transport oat3/Slc22a8 interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 2008; 74: 122-31
18. Issa MM, Nejem RM, El-Abadla NS. Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva. Clin Drug Invest 2006; 26: 223-6
19. Oh YH, Han HK. Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anions transporters in rats. Pharmacol Res 2006; 53: 75-9
20. Shah A, Liu MC, Vaughan D, et al. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 ml or 500 mg/5 ml suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrobiol Chemother 1999; 43 Suppl. A: 49-54
21. Patel KB, Belliveau PP, Nightingale CH, et al. Absorption of ciprofloxacin in febrile and afebrile patients. Int J Antimicrobial Agent 1995; 6: 119-22
22. Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, et al. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2006; 50: 3947-9
23. Jaechde L, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in human. Clin Pharmacol Ther 1995; 58: 532-41